Adam Fisch, MD, PhD | Authors


Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AML

January 11, 2020

Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.